- Home
- EVR vs QGEN Comparison
EVR vs QGEN Comparison
Compare EVR & QGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EVR
- QGEN
- Stock Information
- Founded
- EVR 1995
- QGEN 1986
- Country
- EVR United States
- QGEN Netherlands
- Employees
- EVR N/A
- QGEN N/A
- Industry
- EVR Investment Managers
- QGEN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- EVR Finance
- QGEN Health Care
- Exchange
- EVR Nasdaq
- QGEN Nasdaq
- Market Cap
- EVR 10.4B
- QGEN 9.5B
- IPO Year
- EVR 2006
- QGEN 1996
- Fundamental
- Price
- EVR $272.50
- QGEN $44.67
- Analyst Decision
- EVR Hold
- QGEN Buy
- Analyst Count
- EVR 6
- QGEN 9
- Target Price
- EVR $296.20
- QGEN $51.42
- AVG Volume (30 Days)
- EVR 371.9K
- QGEN 865.8K
- Earning Date
- EVR 01-29-2025
- QGEN 02-04-2025
- Dividend Yield
- EVR 1.16%
- QGEN 2.96%
- EPS Growth
- EVR N/A
- QGEN N/A
- EPS
- EVR 7.79
- QGEN 0.41
- Revenue
- EVR $2,789,086,000.00
- QGEN $1,966,174,000.00
- Revenue This Year
- EVR $21.31
- QGEN $2.78
- Revenue Next Year
- EVR $22.73
- QGEN $5.69
- P/E Ratio
- EVR $35.41
- QGEN $107.74
- Revenue Growth
- EVR 12.78
- QGEN 0.62
- 52 Week Low
- EVR $162.72
- QGEN $39.03
- 52 Week High
- EVR $324.06
- QGEN $47.44
- Technical
- Relative Strength Index (RSI)
- EVR 33.34
- QGEN 54.59
- Support Level
- EVR $290.47
- QGEN $44.02
- Resistance Level
- EVR $302.88
- QGEN $46.08
- Average True Range (ATR)
- EVR 7.59
- QGEN 0.76
- MACD
- EVR -3.52
- QGEN -0.03
- Stochastic Oscillator
- EVR 1.97
- QGEN 41.98
About EVR Evercore Inc.
Evercore is an independent investment bank that derives the majority of its revenue from financial advisory, including merger, acquisition, and restructuring advisory. It also has institutional equities trading, equity underwriting, and investment management businesses that account for around 20% of net revenue. The company was founded in 1996 and went public in 2006. Evercore had approximately 2,200 employees at the end of 2023, and about 75% of its revenue is derived from the United States.
About QGEN Qiagen N.V.
Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2023 sales), followed by EMEA (32%), and the Asia-Pacific (16%).